A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Phase 1

Completed

• Conditions: Schizophrenia
• Interventions: Drug: PF-05180999; Drug: Placebo

• Registration Number: NCT01429740
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2011-08-24
• Study First Submitted QC: 2011-09-06
• Study First Posted: 2011-09-07
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Status Verified: 2012-04
• Last Update Submitted: 2012-04-10
• Last Update Posted: 2012-04-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

male or female of non-childbearing potential,

Exclusion Criteria

Evidence of clinically significant medical illness, history of seizures, any condition possibly affecting drug absorption

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
PF-05180999	PF-05180999	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Composite (or profile) of Pharmacokinetics	0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 hours post-dose on Day 1 and Day 1

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 New Haven, Connecticut, United States